You are here
Final Approval for Pergolide Announced
Pergolide mesylate is the generic equivalent of Permax® tablets marketed by Amarin Corporation PLC for use as an adjunctive treatment in connection with Parkinson’s disease. U.S. sales of Permax during 2002 were approximately $50 million. Pergolide mesylate tablets’ active pharmaceutical ingredient is produced at IVAX’ facility in the Czech Republic, which will also be manufacturing the tablets.
Source: IVAX Corporation